Last updated on July 2013

Type II Diabetic Patients at High Risk For Cardiovascular Events

Brief description of study

Type II Diabetic Patients at High Risk For Cardiovascular Events

Detailed Study Description

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged ≥40 years
  • Diagnosed with Type 2 Diabetes
  • High Risk for Cardiovascular events

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
  • Chronic cystitis and/or recurrent urinary tract infections
  • Pregnant or breast-feeding patients

Please note: Other protocol specific Inclusion/Exclusion Criteria apply. Compensation for time and travel will be provided for each completed visit.

Clinical Study Identifier: TX137075

Find a site near you

Start Over

Cardiology Research Associates

305 Memorial Medical Parkway<br /> Suite 301 Daytona Beach, FL USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.